Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

275
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
275
Global Climate Change01:50

Global Climate Change

29.0K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
29.0K
Introduction to Global Positioning System01:30

Introduction to Global Positioning System

608
The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense  for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...
608
Errors in Global Positioning System01:26

Errors in Global Positioning System

364
Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...
364
Global Regulatory Systems01:28

Global Regulatory Systems

727
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
727
Field Application of Global Positioning System01:28

Field Application of Global Positioning System

333
The Global Positioning System (GPS) has become an indispensable tool in fieldwork, offering unparalleled precision and efficiency for surveying, navigation, and infrastructure development. By harnessing signals from a constellation of satellites, GPS receivers determine the location of objects with remarkable speed and accuracy, often completing calculations within a second.Advantages of Modern GPS TechnologyContemporary GPS receivers are designed to meet the practical demands of field...
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sepiapterin: First Approval.

Drugs·2025
Same author

Tiratricol: First Approval.

Drugs·2025
Same author

Recaticimab: First Approval.

Drugs·2025
Same author

Tasurgratinib Succinate: First Approval.

Drugs·2025
Same author

Correction: Fulzerasib: First Approval.

Drugs·2025
Same author

Marstacimab: First Approval.

Drugs·2024

Related Experiment Video

Updated: Feb 11, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K

Burosumab: First Global Approval.

Yvette N Lamb1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|April 22, 2018
PubMed
Summary
This summary is machine-generated.

Burosumab is a novel antibody treatment for X-linked hypophosphataemia (XLH). It targets fibroblast growth factor 23 (FGF23), increasing phosphate and vitamin D levels to treat this rare bone disease.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Related Experiment Videos

Last Updated: Feb 11, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.7K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • X-linked hypophosphataemia (XLH) is a rare genetic disorder characterized by renal phosphate wasting and hypophosphataemia.
  • Excessive fibroblast growth factor 23 (FGF23) production is a key driver of XLH pathophysiology.
  • Current treatments for XLH have limitations in effectively managing disease manifestations.

Purpose of the Study:

  • To summarize the development of burosumab, a monoclonal antibody targeting FGF23.
  • To highlight the regulatory milestones of burosumab for treating XLH.
  • To provide an overview of ongoing clinical trials evaluating burosumab.

Main Methods:

  • Burosumab is a fully human monoclonal antibody that inhibits FGF23.
  • Clinical trials, including multinational phase III studies, are evaluating burosumab in pediatric and adult XLH patients.
  • Phase II studies are also assessing burosumab for other conditions like tumor-induced osteomalacia.

Main Results:

  • Burosumab treatment leads to increased renal phosphate reabsorption.
  • This results in elevated serum phosphorus and active vitamin D levels.
  • Conditional marketing authorization was granted by EMA in Feb 2018 and FDA approval in April 2018 for XLH treatment.

Conclusions:

  • Burosumab represents a significant advancement in XLH therapy.
  • Its targeted inhibition of FGF23 offers a promising approach to managing XLH.
  • Further clinical trials will continue to define its efficacy and safety profile in various patient populations.